Aerie Pharmaceuticals Logo

News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation - June 8, 2022

OIS Glaucoma Innovation Summit

OIS Retina Innovation Showcase

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Announces $125 Million Convertible Notes
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it
View HTML
Toggle Summary Aerie Announces Closing of $125 Million Convertible Notes Financing
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it
View HTML
Toggle Summary Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
Agreement includes Europe , Commonwealth of Independent States countries, China , India , parts of Latin America and the Oceania countries DURHAM, N.C. --(BUSINESS WIRE)--Dec. 7, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have entered into an
View HTML
Toggle Summary Aerie Pharmaceuticals Added to NASDAQ Biotechnology Index (NBI)
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with
View HTML
TOP